48th ASH™ Annual Meeting and Exposition
December 9-12, 2006

Orange County Convention Center
Orlando, Florida

Meet-the-Expert Sessions

Saturday, December 9, and Sunday, December 10

This year, ASH has scheduled a total of 58 experts from all over the world who will facilitate informal discussions allowing participants to present their questions and gain new perspectives. These sessions will take place at a new time, from 11:15 a.m. – 12:15 p.m., and ticket fees will include a box lunch for each attendee.

Ticket Prices (per session)

ASH members and ASH Associate members: $20
Non-members: $30

Tickets are very limited and only available on site on a first-come, first-served basis. Only one ticket per person is allowed. Please note that the Meet-the-Expert sessions are restricted to registered medical professionals only; no businesspersons or media will be admitted. These tickets can be purchased at the Meet-the-Expert counter in the ASH registration area of the West Building of the Orange County Convention Center starting Thursday, December 7, during the registration hours until all tickets are sold. Each room assignment will be indicated on the ticket. Please check your ticket carefully to ensure proper date, time, location, and session choice.

ATTENTION FELLOWS!

As ASH encourages fellows to participate in these sessions, a number of tickets will be reserved for fellows. Proof of status as an ASH Associate member or non-member in training will be required to purchase a ticket. Please show your name badge to the staff at the Meet-the-Expert ticket counter.

Saturday, December 9, 11:15 a.m. – 12:15 p.m.

Alan K. Burnett, MD, FRCP, Cardiff University School of Medicine , Cardiff, United Kingdom
Acute Myeloid Leukemia in Adults

Andrew Dancis, MD, University of Pennsylvania, Philadelphia, PA
Iron Deficiency and Iron Overload Diagnosis and Treatment

Laurent Degos , MD, PhD, French National Authority for Health, La Plaine Saint Denis, France Management of Acute Promyelocytic Leukemia

Hartmut Döhner, MD, University of Ulm, Ulm, Germany
Genetics of CLL

Elihu H. Estey, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX What’s New in the Management of Myelodysplasias

Francine Foss, MD, Yale Cancer Center, New Haven, CT
Mycosis Fungoides

Alan M. Gewirtz, MD, University of Pennsylvania School of Medicine, Philadelphia, PA
Gene Silencing Therapies for Hematologic Malignancies

Cage S. Johnson, MD, University of Southern California, Los Angeles, CA
Challenges for the Adult Patient with Sickle Cell Disease

Armand Keating, MD, Princess Margaret Hospital, Toronto, Ontario, Canada
The Role of Mesenchymal Stromal Cells in Tissue Regeneration

Mark N. Levine, MD, MSC, Clinical Trials Methodology Group, Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
Thrombosis in Cancer Patients

 Charles Linker, MD, University of California, San Francisco, CA
Acute Lymphoblastic Leukemia in Adults

Catherine Scott Manno, MD, Children’s Hospital of Philadelphia, Philadelphia, PA
Clotting Disorders in Children

Judith Marsh, MD, St. George’s Hospital, St. George’s University of London, London, United Kingdom
The Management of Aplastic Anemia

Ari M. Melnick, MD, Albert Einstein College of Medicine, Bronx, NY
Developing Novel Therapeutics for Malignant Lymphomas

Beverly S. Mitchell, MD, Stanford University Comprehensive Cancer Center, Stanford, CA
Targeted Therapies for Leukemia

Eliezer A. Rachmilewitz, MD, The Edith Wolfson Medical Center, Holon, Israel
Iron Overload in Myelodysplastic Syndrome

Griffin Rodgers, MD, National Insitute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
Hydroxyurea in Sickle Cell Anemia and Hemoglobinopathies

J. F. San Miguel, MD, PhD, Hospital Clinico Universitario, Salamanca, Spain
The Role of Novel Drugs in a Myeloma Transplant Setting

Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
Non-Myeloablative Hematopoietic Cell Transplantation  

Andrew I. Schafer, MD, University of Pennsylvania School of Medicine, Philadelphia, PA
Thrombocytosis

Geraldine P. Schechter, MD, Veterans Affairs Medical Center and George Washington University, Washington, DC
Update on Rituximab Treatment for Autoimmune Hematologic Disorders

David A. Scheinberg, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Antibody and Vaccine Therapy of Acute Myelogenous Leukemia

Charles A. Schiffer, MD, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
Acute Myelogenous Leukemia in the Elderly

Richard T. Silver, MD, New York Hospital, Weill Cornell Medical Center , New York , NY Management of Polycythemia Vera

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
Hodgkin Disease

Ayalew Tefferi, MD, Mayo Clinic, Rochester, MN
Essential Thrombocythemia

Guido J. Tricot, MD, PhD, University of Arkansas for Medical Science, Myeloma Institute for Research and Therapy, Little Rock, AR
Transplant Strategies for Multiple Myeloma

James C. Wade, MD, MPH, Medical College of Wisconsin, Milwaukee, WI
Infections in the Immunosuppressed Host

Cheryl L. Willman, MD, University of New Mexico School of Medicine, Albuquerque, NM Gene Expression Profiling in Acute Leukemia

Sunday, December 10, 11:15 a.m. – 12:15 p.m.

Nancy C. Andrews, MD, PhD, Children’s Hospital Boston and Harvard Medical School, Boston, MA
New Aspects of Iron Metabolism

Kenneth A. Bauer, MD, VA Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Thrombophilia

Nancy Berliner, MD, Yale University School of Medicine, New Haven, CT
Congenital and Acquired Neutropenia

Karl G. Blume, MD, Stanford University Medical Center, Stanford, CA
Transplantation of Allogeneic Hematopoietic Cells

John C. Byrd, MD, The Ohio State University, Columbus, OH
Management of CLL

William L. Carroll, MD, New York University School of Medicine, New York, NY
Optimizing Treatment for T-Cell Acute Lymphoblastic Leukemia in Children

Barry S. Coller, MD, The Rockefeller University, New York, NY
The Joys and Challenges of Translational Research

Mark A. Crowther, MD, MSc, St. Joseph’s Hospital, McMaster University, Hamilton, Ontario, Canada
The Latest on DVT

Myron S. Czuczman, MD, Roswell Park Cancer Institute, Buffalo, NY
Rituximab and Beyond: Current and Future Use of Antibodies in B-Cell Lymphoma

Michael W. N. Deininger, MD, PhD, Oregon Health & Science University, Portland, OR
New Inhibitors of BCR-ABL and the Role in Mangement of CML

Volker Diehl, MD, Koln University, Koln, Germany
Insights into the Biology and Management of Hodgkin Disease

Stephen G. Emerson, MD, PhD, University of Pennsylvania, Philadelphia, PA
Osteoblasts and Marrow Stem Cells

Varsha Gandhi, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX Nucleoside Analogs in Leukemia

John M. Goldman, DM, FRCP, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD Management of CML in the Imatinib Era

Peter L. Greenberg, MD, Stanford University, Stanford, CA
Management of Myelodysplasia

Ronald Hoffman, MD, University of Illinois at Chicago College of Medicine, Chicago, IL
Biology and Treatment of Idiopathic Myelofibrosis

Mark S. Kaminski, MD, University of Michigan Cancer Center, Ann Arbor, MI
Radioimmunotherapy of Lymphoma

Lawrence Kaplan, MD, University of California, San Francisco, CA
HIV-Associated Lymphomas

Kenneth Kaushansky, MD, University of California at San Diego, San Diego, CA
JAK Mutations in Myeloproliferative Syndromes

Thomas J. Kipps, MD, PhD, University of California at San Diego, San Diego, CA
Novel Therapies on the Horizon for Chronic Lymphocytic Leukemia

Harvey G. Klein, MD, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
Progress in Blood Substitutes and Transfusion Medicine

Junia V. Melo, MD, PhD, Imperial College, Hammersmith Hospital, London, United Kingdom
Molecular Aspects of Chronic Myelogenous Leukemia

Man-Chiu Poon, MD, University of Calgary, Foothills Hospital, Calgary, Alberta, Canada
Use of Recombinant Coagulation Factors

Miles Prince, MD, Peter MacCallum Cancer Institute, Melbourne, Australia
Treatment Options for the Management of Advanced-Stage Cutaneous Lymphomas

Mariusz Ratajczak , MD, PhD, University of Louisville, James Graham Brown Cancer Center, Louisville, KY
Adult Marrow-Derived Very Small Embryonic Like (VSEL) Stem Cells and Tissue Engineering

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA
New Agents in the Treatment of Multiple Myeloma

J. Evan Sadler, MD, PhD, Washington University Medical School, Howard Hughes Medical Institute, St. Louis, MO
Von Willebrand Disease and Thrombotic Thrombocytopenic Purpura: United by ADAMTS13

Warren Shlomchik, MD, Yale University School of Medicine, New Haven, CT
New Concepts in Graft-Versus-Host Disease

Leslie E. Silberstein, MD, Children’s Hospital Boston, Boston, MA
Blood and Cell Processing for Stem Cell Transplantation and Gene Therapy